Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Physostigmine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Atropine | DRUG | 10 ug/kg bolus, 4 ug/kg/h infusion |
| Physostigmine | DRUG | 0,12ug/kg/min |
| Placebo Sodium | DRUG | - |
Inclusion Criteria: * Signed written informed consent * BMI of lean and abdominally obese men and women * weight stable Exclusion Criteria: * Ongoing clinically significant diseases * History of repeated syncope * resting pulse\<50 or systolic blood pressure \<100
Physostigmine is being studied as an investigational small molecule for insulin resistance. AstraZeneca PLC is developing it, and it has completed one early Phase 1 trial in this metabolic indication. It is not an approved treatment for insulin resistance.
Physostigmine targets acetylcholinesterase, also known as ACHE. It acts as an inhibitor of this enzyme. This mechanism is being explored in a metabolic context for insulin resistance, though the drug remains investigational.
AstraZeneca PLC is developing Physostigmine. The company trades under the ticker AZN. The drug is a small molecule being investigated for insulin resistance.
Physostigmine is in Phase 1 development. One early Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational drug and has not been approved for any indication.
Physostigmine has been studied in one completed clinical trial, NCT00689208, titled Pharmacological Intervention in Insulin Resistance Targeting Autonomic Nerve Activity. The early Phase 1 trial enrolled 12 participants in Sweden and included healthy volunteers.